Furthermore, there have been no prospective randomized trials to investigate the role of CCRT in SCN+ stage IIIB NSCLC, and such trials may not be easy to perform because the proportion of SCN+ patients is relatively small. The gene discussed is SRI; the disease is non-small cell lung carcinoma.